RxDoctor Payments Data

Briana Kudick

Family · Green Bay, WINPI 1063898757

Payments from drug & device makers

$1,952in general payments, 2019–2025

Across 73 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Boston Scientific$234
  • Cvrx, Inc.$128
  • AstraZeneca$118
  • Boehringer Ingelheim$81
  • Bridgebio Pharma, Inc.$51
  • plus $133 from 5 others

What the payments were for

  • Food & beverage$1,952100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,952 in reported general payments places this provider in the 90th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$14,617
Medicare patients
157
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$133,154
EntrestoSacubitril/Valsartan52$56,908
XareltoRivaroxaban32$44,186
Repatha SureclickEvolocumab45$36,477
FarxigaDapagliflozin Propanediol31$27,963
JardianceEmpagliflozin29$21,186
Atorvastatin Calcium180$1,886
Metoprolol Succinate152$1,718
Ezetimibe80$1,270
Rosuvastatin Calcium96$1,196
Losartan Potassium69$931
Amiodarone Hcl17$907
Bumetanide17$864
ClopidogrelClopidogrel Bisulfate65$843
Furosemide109$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,208$56,90852 claims
AstraZenecaFarxiga$118$27,96331 claims
Boehringer IngelheimJardiance$81$21,18629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,273 family providers in Wisconsin.

Other family in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →